Catheter Precision, Inc. (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.
All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota. The company maintains in-house capabilities for rapid prototyping, tooling, extrusion and assembly, enabling tight control over quality and production timelines. In addition to its proprietary balloon catheter lines, Catheter Precision offers contract manufacturing services and technical support to other medical device firms, leveraging its expertise in catheter extrusion, balloon bonding and catheter tip formation.
Originally incorporated as Vascular Technologies, Inc., the company adopted the Catheter Precision name in mid-2023 to better reflect its focus on high-performance catheter solutions. While headquartered in the United States, Catheter Precision serves hospitals, outpatient clinics and interventional labs globally through a network of direct sales and independent distributors across North America, Europe, Latin America and select markets in Asia. The company continues to invest in product innovation, clinical collaborations and regulatory clearances to expand its geographic footprint and therapeutic offerings.
AI Generated. May Contain Errors.
Free VTAK Stock Alerts